

David A Tulis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8851694/publications.pdf>

Version: 2024-02-01

54
papers

1,405
citations

393982

19
h-index

329751

37
g-index

54
all docs

54
docs citations

54
times ranked

1845
citing authors

#	ARTICLE	IF	CITATIONS
1	The Influence of Maternal Aerobic Exercise, Blood DHA and EPA Concentrations on Maternal Lipid Profiles. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3550.	1.2	9
2	Protease-Activated Receptor-2 Differentially Regulates Vascular Smooth Muscle Cell Proliferation in Cyclic AMP-Dependent Protein Kinase/Phosphoinositide 3-Kinase-Dependent Manner. <i>FASEB Journal</i> , 2022, 36, .	0.2	0
3	Maternal Aerobic Exercise, but Not Blood Docosahexaenoic Acid and Eicosapentaenoic Acid Concentrations, during Pregnancy Influence Infant Body Composition. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 8293.	1.2	4
4	Increased AMP deaminase activity decreases ATP content and slows protein degradation in cultured skeletal muscle. <i>Metabolism: Clinical and Experimental</i> , 2020, 108, 154257.	1.5	17
5	Cyclic Nucleotide-Directed Protein Kinases in Cardiovascular Inflammation and Growth. <i>Journal of Cardiovascular Development and Disease</i> , 2018, 5, 6.	0.8	6
6	Abstract 549: Interleukin-6 Trans-Signaling in Acute Myocardial Infarction in Male BALB/c Mice. <i>Circulation Research</i> , 2018, 123, .	2.0	0
7	Making the cut: Innovative methods for optimizing perfusion-based migration assays. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2017, 91, 270-280.	1.1	0
8	Novel protein kinase targets in vascular smooth muscle therapeutics. <i>Current Opinion in Pharmacology</i> , 2017, 33, 12-16.	1.7	3
9	Soluble guanylyl cyclase-activated cyclic GMP-dependent protein kinase inhibits arterial smooth muscle cell migration independent of VASP-serine 239 phosphorylation. <i>Cellular Signalling</i> , 2016, 28, 1364-1379.	1.7	20
10	Abstract 556: The Soluble Guanylyl Cyclase Activator Bay 60-2770 Inhibits Arterial Smooth Muscle Cell Migration in Protein Kinase G-dependent Manner. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, .	1.1	0
11	Vascular Smooth Muscle as a Therapeutic Target in Disease Pathology. , 2015, , .		1
12	AMP-activated protein kinase inhibits transforming growth factor- β -mediated vascular smooth muscle cell growth: implications for a Smad-3-dependent mechanism. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2015, 309, H1251-H1259.	1.5	16
13	Connexins and intercellular communication in arterial growth and remodeling. <i>Archives of Physiology</i> , 2015, 2, 1.	0.0	2
14	Exchange protein activated by cAMP (EPAC) controls migration of vascular smooth muscle cells in concentration- and time-dependent manner. <i>Archives of Physiology</i> , 2015, 2, 2.	0.0	5
15	Protein Kinase G and VASP in the Control of Vascular Smooth Muscle Cell Migration. <i>FASEB Journal</i> , 2015, 29, 804.5.	0.2	0
16	AMP-activated protein kinase inhibits vascular smooth muscle cell proliferation and migration and vascular remodeling following injury. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2013, 304, H369-H381.	1.5	67
17	The Dopamine D3 Receptor Knockout Mouse Mimics Aging-Related Changes in Autonomic Function and Cardiac Fibrosis. <i>PLoS ONE</i> , 2013, 8, e74116.	1.1	23
18	Experimental Rat and Mouse Carotid Artery Surgery: Injury and Remodeling Studies. <i>ISRN Minimally Invasive Surgery</i> , 2013, 2013, 1-10.	0.3	27

#	ARTICLE	IF	CITATIONS
19	Inhibition of Vascular Smooth Muscle Growth by the Soluble Guanylyl Cyclase Activator BAY 602770. <i>FASEB Journal</i> , 2013, 27, 1139.3.	0.2	0
20	Abstract 297: Cyclic GMP Reduces Vascular Smooth Muscle Migration through Inhibition of TGF- β 1/Smad Signaling. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, .	1.1	0
21	Control of Vascular Smooth Muscle Cell Growth by Connexin 43. <i>Frontiers in Physiology</i> , 2012, 3, 220.	1.3	23
22	Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells. <i>Frontiers in Pharmacology</i> , 2012, 3, 10.	1.6	16
23	Bilirubin Inhibits Neointima Formation and Vascular Smooth Muscle Cell Proliferation and Migration. <i>Frontiers in Pharmacology</i> , 2012, 3, 48.	1.6	37
24	Inhibition of vascular smooth muscle growth via signaling crosstalk between AMP-activated protein kinase and cAMP-dependent protein kinase. <i>Frontiers in Physiology</i> , 2012, 3, 409.	1.3	30
25	The dopamine D3 receptor knockout mouse models aging-related changes in hypertension and cardiac fibrosis. <i>FASEB Journal</i> , 2012, 26, 1092.11.	0.2	0
26	DINITROBENZENES STIMULATE ELECTRON FLUX WITHIN NEURONAL NITRIC OXIDE SYNTHASE IN THE ABSENCE OF CALMODULIN. <i>International Journal of Biomedical Research</i> , 2011, 2, 499-507.	0.1	0
27	The Soluble Guanylate Cyclase Stimulator BAY 41-2272 Inhibits Vascular Smooth Muscle Growth through the cAMP-Dependent Protein Kinase and cGMP-Dependent Protein Kinase Pathways. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011, 339, 394-402.	1.3	45
28	BAY 412272 increases VASP phosphorylation via increases in both cAMP and cGMP in rat primary VSMCs. <i>FASEB Journal</i> , 2011, 25, 1008.4.	0.2	0
29	Differential regulation of vascular growth through cGMP/PK β /PK α signaling. <i>FASEB Journal</i> , 2011, 25, 1026.30.	0.2	0
30	BAY 412272 reduces vascular smooth muscle cell growth via PK β & PK α signals. <i>FASEB Journal</i> , 2010, 24, 603.2.	0.2	0
31	YC-1 Stimulates the Expression of Gaseous Monoxide-Generating Enzymes in Vascular Smooth Muscle Cells. <i>Molecular Pharmacology</i> , 2009, 75, 208-217.	1.0	18
32	Arginase Promotes Neointima Formation in Rat Injured Carotid Arteries. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2009, 29, 488-494.	1.1	59
33	The Cyclic GMP Modulators YC-1 and Zaprinast Reduce Vessel Remodeling Through Antiproliferative and Proapoptotic Effects. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2009, 14, 116-124.	1.0	9
34	Antigrowth Properties of BAY 41-2272 in Vascular Smooth Muscle Cells. <i>Journal of Cardiovascular Pharmacology</i> , 2009, 53, 121-131.	0.8	19
35	Novel Therapies for Cyclic GMP Control of Vascular Smooth Muscle Growth. <i>American Journal of Therapeutics</i> , 2008, 15, 551-564.	0.5	17
36	YC-1 stimulates heme oxygenase-1 gene expression in vascular smooth muscle cells. <i>FASEB Journal</i> , 2008, 22, 749.3.	0.2	0

#	ARTICLE	IF	CITATIONS
37	Pharmacologic Modulators of Soluble Guanylate Cyclase/Cyclic Guanosine Monophosphate in the Vascular System - From Bench Top to Bedside. <i>Current Vascular Pharmacology</i> , 2007, 5, 1-14.	0.8	2
38	Endocannabinoid Regulation of Matrix Metalloproteinases: Implications in Ischemic Stroke. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2007, 5, 311-318.	0.4	6
39	Rat Carotid Artery Balloon Injury Model. <i>Methods in Molecular Medicine</i> , 2007, 139, 1-30.	0.8	101
40	Histological and Morphometric Analyses for Rat Carotid Balloon Injury Model. <i>Methods in Molecular Medicine</i> , 2007, 139, 31-66.	0.8	25
41	Pharmacologic Modulators of Soluble Guanylate Cyclase/Cyclic Guanosine Monophosphate in the Vascular System - From Bench Top to Bedside. <i>Current Vascular Pharmacology</i> , 2007, 5, 1-14.	0.8	2
42	Pharmacologic modulators of soluble guanylate cyclase/cyclic guanosine monophosphate in the vascular system - from bench top to bedside. <i>Current Vascular Pharmacology</i> , 2007, 5, 1-14.	0.8	14
43	Methods for Identifying Cardiovascular Agents: A Review. <i>Recent Patents on Cardiovascular Drug Discovery</i> , 2006, 1, 47-56.	1.5	7
44	Curcumin Inhibits Platelet-Derived Growth Factor-Induced Vascular Smooth Muscle Cell Function and Injury-Induced Neointima Formation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2006, 26, 85-90.	1.1	128
45	Nitric oxide-generating hydrogels inhibit neointima formation. <i>Journal of Biomaterials Science, Polymer Edition</i> , 2005, 16, 659-672.	1.9	49
46	Salutary Properties of YC-1 in the Cardiovascular and Hematological Systems. <i>Current Medicinal Chemistry Cardiovascular and Hematological Agents</i> , 2004, 2, 343-359.	1.7	17
47	Adenoviral Gene Transfer of Fortilin Attenuates Neointima Formation Through Suppression of Vascular Smooth Muscle Cell Proliferation and Migration. <i>Circulation</i> , 2003, 107, 98-105.	1.6	31
48	Steroid Receptor Coactivator-3 Is Required for Inhibition of Neointima Formation by Estrogen. <i>Circulation</i> , 2002, 105, 2653-2659.	1.6	78
49	YC-1-Mediated Vascular Protection through Inhibition of Smooth Muscle Cell Proliferation and Platelet Function. <i>Biochemical and Biophysical Research Communications</i> , 2002, 291, 1014-1021.	1.0	55
50	Heme oxygenase-1 attenuates vascular remodeling following balloon injury in rat carotid arteries. <i>Atherosclerosis</i> , 2001, 155, 113-122.	0.4	138
51	Adenovirus-Mediated Heme Oxygenase-1 Gene Delivery Inhibits Injury-Induced Vascular Neointima Formation. <i>Circulation</i> , 2001, 104, 2710-2715.	1.6	164
52	YC-1, a Benzyl Indazole Derivative, Stimulates Vascular cGMP and Inhibits Neointima Formation. <i>Biochemical and Biophysical Research Communications</i> , 2000, 279, 646-652.	1.0	47
53	Medial and Endothelial Platelet-Derived Growth Factor A Chain Expression Is Regulated by in vivo Exposure to Elevated Flow. <i>Journal of Vascular Research</i> , 1998, 35, 413-420.	0.6	14
54	Flow-induced arterial remodeling in rat mesenteric vasculature. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1998, 274, H874-H882.	1.5	54